Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
58.75 x 10 58.83 x 3
Post-market by (Cboe BZX)
58.08 -4.80 (-7.63%) 04/17/25 [NYSE]
58.75 x 10 58.83 x 3
Post-market 58.80 +0.72 (+1.24%) 19:59 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
57.28
Day High
59.06
Open 57.91
Previous Close 62.88 62.88
Volume 32,220,600 32,220,600
Avg Vol 9,709,370 9,709,370
Stochastic %K 28.08% 28.08%
Weighted Alpha -60.64 -60.64
5-Day Change -3.13 (-5.11%) -3.13 (-5.11%)
52-Week Range 57.28 - 148.15 57.28 - 148.15
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 260,635,872
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 42,108 M
  • Annual Income, $ 14,643 M
  • EBIT $ 18,609 M
  • EBITDA $ 21,380 M
  • 60-Month Beta 0.61
  • Price/Sales 6.70
  • Price/Cash Flow 16.20
  • Price/Book 13.56

Options Overview Details

View History
  • Implied Volatility 52.89% ( -10.06%)
  • Historical Volatility 55.11%
  • IV Percentile 91%
  • IV Rank 61.99%
  • IV High 70.99% on 04/08/25
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.98
  • Today's Volume 84,735
  • Volume Avg (30-Day) 40,519
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 524,741
  • Open Int (30-Day) 469,639

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.91
  • Number of Estimates 4
  • High Estimate 0.94
  • Low Estimate 0.88
  • Prior Year 0.83
  • Growth Rate Est. (year over year) +9.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.28 +1.40%
on 04/17/25
Period Open: 80.15
82.57 -29.66%
on 03/18/25
-22.07 (-27.54%)
since 03/17/25
3-Month
57.28 +1.40%
on 04/17/25
Period Open: 78.69
93.80 -38.08%
on 02/25/25
-20.61 (-26.19%)
since 01/17/25
52-Week
57.28 +1.40%
on 04/17/25
Period Open: 124.53
148.15 -60.80%
on 06/25/24
-66.45 (-53.36%)
since 04/17/24

Most Recent Stories

More News
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's no wonder Wall Street investment banks are telling anyone who will listen that...

NVO : 58.08 (-7.63%)
MS : 109.18 (+1.22%)
LLY : 839.96 (+14.30%)
Where Will Eli Lilly Be in 5 Years?

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY) . In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer , and Merck...

NVO : 58.08 (-7.63%)
MRK : 78.00 (+2.01%)
JNJ : 157.47 (+2.31%)
LLY : 839.96 (+14.30%)
PFE : 22.14 (+0.45%)
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

VKTX : 23.94 (+1.44%)
NVO : 58.08 (-7.63%)
HIMS : 27.23 (+1.04%)
LLY : 839.96 (+14.30%)
PFE : 22.14 (+0.45%)
Viking Therapeutics Stock Pops But Struggles to Hold Gains

VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington

VKTX : 23.94 (+1.44%)
NVO : 58.08 (-7.63%)
LLY : 839.96 (+14.30%)
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved

The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.

APIE : 29.28 (+1.24%)
NVO : 58.08 (-7.63%)
AVDE : 66.27 (+1.10%)
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While AbbVie also markets products for aesthetics, neuroscience and eye care, Merck has...

NVO : 58.08 (-7.63%)
MRK : 78.00 (+2.01%)
LLY : 839.96 (+14.30%)
ABBV : 172.99 (+0.76%)
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Pfizer bows, but is not entirely out of the GLP-1 race.

VKTX : 23.94 (+1.44%)
NVO : 58.08 (-7.63%)
LLY : 839.96 (+14.30%)
GPCR : 21.76 (+17.43%)
PFE : 22.14 (+0.45%)
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs

The stock market was on a roller coaster on April 9 amid the ongoing global trade war triggered by a new series of tariffs by the U.S. government. Most of the pharma bigwigs ended the trading session in...

AZN : 67.59 (+0.81%)
NVO : 58.08 (-7.63%)
LLY : 839.96 (+14.30%)
ABBV : 172.99 (+0.76%)
Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

HIMS : 27.23 (+1.04%)
NVO : 58.08 (-7.63%)
LLY : 839.96 (+14.30%)
5 Top Growth Stocks to Buy in the Stock Market Sell-Off

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean investors should avoid buying stocks right now -- quite the contrary. History tells...

SHOP : 83.65 (-0.37%)
NVO : 58.08 (-7.63%)
LLY : 839.96 (+14.30%)
VRTX : 489.10 (+0.66%)
ISRG : 482.74 (+0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 60.78
2nd Resistance Point 59.92
1st Resistance Point 59.00
Last Price 58.08
1st Support Level 57.22
2nd Support Level 56.36
3rd Support Level 55.44

See More

52-Week High 148.15
Fibonacci 61.8% 113.44
Fibonacci 50% 102.71
Fibonacci 38.2% 91.99
Last Price 58.08
52-Week Low 57.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro